Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical
Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUOLatest Information Update: 10 Feb 2025
At a glance
- Originator WuXi Biologics
- Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer; Hodgkin's disease
- Phase III Gastrointestinal cancer; Non-small cell lung cancer
- Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
- Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
- No development reported Cancer; Glioblastoma
- Discontinued Prostate cancer
Most Recent Events
- 23 Jan 2025 Arcus Biosciences completes the phase I trial for Cancer (Combination therapy, Late-stage disease) in Australia, USA (IV) (NCT03628677)
- 18 Nov 2024 Arcus Biosciences completes the phase I ARC-4 trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in Taiwan, Singapore, South Korea (IV) (NCT03846310)
- 05 Nov 2024 Efficacy and adverse event data from a phase III clinical trials in Non-small cell lung cancer released by Arcus Biosciences